Aguilar-Salinas C, Melgarejo-Hernández MA

Language: Spanish
References: 28
Page: 113-122
PDF size: 102.44 Kb.

ABSTRACT

HDL cholesterol is a prognostic factor for the incidence of cardiovascular events. However, its predictive power is lost in conditions in which the HDL composition is altered without changing the cholesterol content of the particle (e.g. chronic inflammatory conditions, apoA-I Milano or the cholesterol ester transfer protein deficiency ). Based on that, there is a need for clinical tests that measure the HDL function or composition. It has been published methods that measure the capacity of HDL particles to prevent LDL oxidation or to diminish monocyte migration or that assess the lipid and protein composition (sing mass espectrometry). For example, the HDL inflammatory index (an in vitro assay) is a better predictor of the carotid grosor than HDL cholesterol in women with lupus. By using mass espectrometry it has been identified that low HDL cholesterol cases has a lower sphingomyelin content and higher amounts of ethanolamine plasmalogen in their HDL3 particles. These changes have functional implications, since phospolipid composition determines the protein content at the HDL surface. Cases with coronary heart disease have HDL3 enriched with apoCIV, paraoxonase 1, C3 complement, apoAIV, apoE and several proteinases inhibitors. Although the evidence is still preliminary, there are some markers of HDL function that may be useful in the future to provide complementary information to that derived from HDL cholesterol levels.

REFERENCES

1. Córdova-Villalobos JA, Barriguete-Meléndez JA, Lara-Esqueda A et al. Chronic non-communicable diseases in Mexico: epidemiologic synopsis and integral prevention. Salud Publica Mex 2008; 50: 419-427.

2. Aguilar-Salinas CA, Gómez PFJ, Rull JA, Villalpando S, Barquera S, Rojas R. Prevalence of dyslipidemias in the 2006. Encuesta Nacional de Salud y Nutrición. Salud Publica Mex 2010; 52: S44-S53.

3. Aguilar-Salinas CA, Olaiz G, Valles V et al. High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nationwide survey. J Lipid Res 2001; 42: 1298-1307.

4. Barquera S, Flores M, Olaiz-Fernández G et al. Dyslipidemias and obesity in Mexico. Salud Publica Mex 2007; 49: S338-S347.

5. Holleboom AG, Vergeer M, Hovingh K, Kastelein J, Kuivenhoven JA. The value of HDL genetics. Cur Opin Lipidol 2008; 19: 385-394.

6. Yvan-Charvet L, Pagler T, Gautier E et al. ATP-Binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science 2010; 328: 1689-1693.

7. Gertz G, Reardon C. High-Density lipoprotein function in regulating insulin secretion: possible relevance to metabolic syndrome. Arterioscler Thromb Vasc Biol 2010; 30: 1497-1499.

8. Pérez-Méndez O, Luc G, Posadas-Romero C. Concentraciones bajas de lipoproteínas de alta densidad (HDL) en plasma y enfermedad arterial coronaria. Arch Inst Cardiol Méx 2000; 70: 312-321.

9. Warnick GR, McNamara J, Boggess C et al. Polycrylamide gradient gel electrophoresis of lipoprotein subclasses. Clin Lab Med 2006; 26: 803-846.

10. Vittone F, Chait A, Morse JS et al. Niacin plus simvastatin reduces coronary stenosis progression among patients with metabolic syndrome despite a modest increase in insulin resistance: A subgroup analysis of the HDL-Atherosclerosis Treatment Study (HATS). J Clin Lipidol 2007; 1: 203-210.

11. Saks FM. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 2002; 90: 139-142.

12. The emerging risk factors collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302: 1993-2000.

13. Calabresi L, Sirtori CR, Paoletti R, Franceschini G. Recombinant apolipoprotein A-I Milano for the treatment of cardiovascular diseases. Curr Atheroscler Rep 2006; 8: 163-167.

14. Shah P. The Yin and Yang of cholesteryl ester transfer protein in cardiovascular disease. Circulation 2009; 120: 2408-2410.

15. Vasan R, Pencina M, Robins S et al. Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community. Circulation 2009; 120: 2414-2420.

16. Navab M, Reddy S, Van Lenten B et al. The role of dysfunctional HDL in atherosclerosis. J Lipid Res 2009; 50: S145–S149.

17. Shao B, Pennathur S, Pagani I, Oda M, Witztum J, Oram J, Heinecke JW. Dysfunctional HDL: modifying apolipoprotein A-I by malondialdehyde, but not by an array of other reactive carbonyls blocks cholesterol efflux by the ABCA1 pathway. J Biol Chem 2010; 285: 18473-18484.

18. Tsompanidi E, Brinkmeier M, Fotiadou E, Giakoumi SM, Kypreos K. HDL biogenesis and functions: Role of HDL quality and quantity in atherosclerosis. Atherosclerosis 2010; 208: 3-9.

19. Hahn B, Grossman J, Ansell BJ et al. Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid artritis. Arthritis Research & Therapy 2008; 10: 213-225.

20. McMahon M, Grossman J, Skaggs B et al. Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheumatism 2009; 60: 2428-2437.

21. Navab M, Hama S, Hough G et al. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res 2001; 42: 1308-1317.

22. Navab M, Imes S, Hama SY et al. Monocyte transmigration induced by modification of low density lipoprotein in co-cultures of human aortic wall cells is due to induction of monocyte chemotactic protein-1 synthesis and is abolished by high density lipoprotein. J Clin Invest 1991; 88: 2039-2046.

23. Yetukuri L, Söderlund S, Koivuniemi A et al. Composition and lipid spatial distribution of HDL particles in subjects with low and high HDL-cholesterol J Lipid Res 2010; 51: 2341-2351.

24. Davidsson P, Hulthe J, Fagerberg B, Camejo G. High-Density lipoproteins proteomics of apolipoproteins and associated proteins from plasma. Arterioscler Thromb Vasc Biol 2010; 30: 156-163.

25. Vaisar T, Pennathur S, Green PS et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007; 117: 746-756.

26. Davidson WS, Silva G, Chantepie G, Lagor W, Chapman J, Kontush A. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler Thromb Vasc Biol 2009; 29: 870-876.

27. Davidson W, Gangani R, Silva D, Chantepie S, Lagor W, Chapman J, Kontush A. Proteomic analysis of Defined HDL subpopulations reveals particle-specific protein clusters: Relevance to antioxidative function. Arterioscler Thromb Vasc Biol 2009; 29: 870-876.

28. Aguilar-Salinas CA, Canizales-Quinteros S, Rojas-Martínez R et al. Hypoalphalipoproteinemia in populations of Native American ancestry: an opportunity to assess the interaction of genes and the environment. Curr Opin Lipidol 2009; 20: 92-97.